All News
Filter News
Found 277 articles
-
Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights
5/15/2023
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the quarter ended March 31, 2023.
-
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results
5/9/2023
Xilio Therapeutics, Inc. today announced pipeline progress and business updates and reported financial results for the first quarter ended March 31, 2023.
-
FDA Conditionally Approves First Drug for Anemia in Cats with Chronic Kidney Disease
5/1/2023
The U.S. Food and Drug Administration conditionally approved Varenzin-CA1, the first drug for the control of nonregenerative anemia associated with chronic kidney disease in cats.
-
Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors
4/20/2023
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux) today announced the first patient has been dosed at City of Hope in a Phase 1 clinical trial of JANX008 in subjects with advanced or metastatic solid tumors including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
-
Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update
3/28/2023
Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today reported financial results for the full year 2022 and provided corporate updates.
-
Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results
3/2/2023
Xilio Therapeutics, Inc. announced pipeline progress and business updates and reported financial results for the fourth quarter and full year ended December 31, 2022.
-
TEZSPIRE® approved for self-administration in the US with a new pre-filled pen
2/2/2023
AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab-ekko) has been approved in the US for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma.
-
TEZSPIRE® APPROVED FOR SELF-ADMINISTRATION IN THE U.S. WITH A NEW PRE-FILLED PEN
2/2/2023
Amgen (NASDAQ:AMGN) and AstraZeneca today announced the U.S. Food and Drug Administration (FDA) has approved TEZSPIRE® (tezepelumab-ekko) for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma.
-
NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities
1/9/2023
NGM Biopharmaceuticals, Inc. is providing an overview of highlights from 2022 and outlining its 2023 corporate priorities.
-
Moderna and CytomX ink a cancer partnership.
-
Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors
12/27/2022
Janux Therapeutics, Inc. announced that the Company has submitted the investigational new drug application for JANX008 to the U.S. Food and Drug Administration, an EGFR-TRACTr in development for the treatment of EGFR-expressing solid tumors, including non-small cell lung cancer, colorectal cancer, renal cell carcinoma, and squamous cell carcinoma of the head and neck.
-
PhoreMost and ThinkCyte Collaborate to Advance AI-based Drug Discovery
12/13/2022
PhoreMost Ltd. and ThinkCyte K.K. announced a strategic research partnership aimed at advancing modern phenotypic drug screening using artificial intelligence.
-
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results
11/9/2022
Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress, business updates and reported financial results for the third quarter ended September 30, 2022.
-
Severely Stressful Events Worsen Symptoms of Long COVID
11/9/2022
The death of a loved one, financial or food insecurity, or a newly developed disability were some of the strongest predictors of whether a patient hospitalized for COVID-19 would experience symptoms of long COVID a year later, a new study finds.
-
NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results
11/3/2022
NGM Biopharmaceuticals, Inc., a clinical-stage biotechnology company focused on discovering and developing transformative therapeutics for patients, provided business highlights and reported financial results for the quarterly period ended September 30, 2022.
-
NGM Bio Announces Presentation of Post-Hoc Analyses from CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) at The Retina Society Annual Scientific Meeting
11/3/2022
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) today announced the presentation of findings from post-hoc analyses of its randomized, double-masked, sham-controlled CATALINA Phase 2 trial of NGM621, a monoclonal antibody designed to inhibit activity of complement component 3 (C3), in patients with GA secondary to AMD at The Retina Society Annual Scientific Meeting taking place November 2 – 5, 2022 in Pasadena, Calif.
-
NGM Bio Announces Topline Results from the CATALINA Phase 2 Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
10/17/2022
NGM Biopharmaceuticals, Inc. today announced topline efficacy and safety results from its randomized, double-masked, sham-controlled CATALINA Phase 2 trial of NGM621 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
-
Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer
10/12/2022
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux) today announced the first patient has been dosed in a Phase 1 clinical trial of JANX007 in subjects with metastatic castration-resistant prostate cancer (mCRPC).
-
Boston Heart Diagnostics Launches LipoMap™: One of the Most Comprehensive Assessments of Lipid Metabolism Available
10/3/2022
Boston Heart Diagnostics is pleased to announce the availability of LipoMap™.
-
Candel Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for CAN-2409 in Glioma
9/15/2022
Candel Therapeutics, Inc. today announced that the European Medicines Agency (EMA) Committee for Orphan Medical Products (COMP) has issued a positive opinion on the Company’s application for orphan drug designation for CAN-2409 for the treatment of glioma.